Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069885 | 0.77 | HDAC3 (0.43) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL560847 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL4854749 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL2003169 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL11353696 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL30385312 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL13932579 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL1564351 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL29612167 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL6298168 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113278036-B | Phenothiazine-containing iridium complex and preparation method and application thereof | 赣南师范大学 | 2022-04-12 | — | — | CN | claimed |
| CN-113336799-B | Dicyano-containing iridium complex and preparation method and application thereof | 赣南师范大学 | 2022-04-12 | — | — | CN | claimed |
| CN-113336799-A | Dicyano-containing iridium complex and preparation method and application thereof | 赣南师范大学 | 2021-09-03 | — | — | CN | claimed |
| CN-113278036-A | Phenothiazine-containing iridium complex and preparation method and application thereof | 赣南师范大学 | 2021-08-20 | — | — | CN | claimed |
| CN-113072496-A | Preparation method of isoquinoline-1-formamide compound | 湖北工业大学 | 2021-07-06 | — | — | CN | claimed |
| CN-102875542-B | Oxadiazole group-containing red-light emitting iridium complex, and preparation method and use thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2015-07-01 | — | — | CN | claimed |
| CN-102875542-A | Oxadiazole group-containing red-light emitting iridium complex, and preparation method and use thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2013-01-16 | — | — | CN | claimed |
| US-7776888-B2 | such as 3-[2-(2-methoxy-ethoxymethyl)-6-trifluoromethyl-pyridine-3-carbonyl]-1,5-dimethyl-8-oxa-bicyclo[3.2.1]oct-6-ene-2,4-dione, used for controlling undesired plant growth or weeds | SYNGENTA CROP PROTECTION, INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20060052247-A1 | Novel herbicides | SYNGENTA CROP PROTECTION, INC. | 2006-03-09 | — | — | US | claimed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-02-20 | — | — | US | disclosed |
| US-11495755-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-11-08 | — | — | US | disclosed |
| US-20030220498-A1 | Iron catalyzed cross coupling reactions of aromatic compounds | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2003-11-27 | — | — | US | disclosed |
| WO-2003033617-A1 | PHOSPHORESCENT COMPOUNDS AND DEVICES COMPRISING THE SAME | UNIVERSAL DISPLAY CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030072964-A1 | Phosphorescent compounds and devices comprising the same | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2003-04-17 | — | — | US | disclosed |
| EP-0970054-A1 | 1-(ISOQUINOLIN-1-YL)-4-(1-PHENYLMETHYL)PIPERAZINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-01-12 | — | — | EP | disclosed |
| US-6008352-A | USEFUL IN TREATING PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1998039301-A1 | 1-(ISOQUINOLIN-1-YL)-4-(1-PHENYLMETHYL)PIPERAZINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN2, PTPN5 | HDAC3 1272/4885HSD17B3 2910/4885PARP1 4454/4885 |
| US-11495755-B2 | Organic electroluminescent materials and devices | RUVBL2, TERT, OR10J3 | HDAC3 2592/4885HSD17B3 3274/4885PARP1 566/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | HDAC3 2217/4885HSD17B3 3052/4885PARP1 3576/4885 |
| US-20030072964-A1 | Phosphorescent compounds and devices comprising the same | NUDC, ORC3, PAICS | HDAC3 3227/4885HSD17B3 4795/4885PARP1 153/4885 |
| US-20060052247-A1 | Novel herbicides | DDT, CYP4F11, CYP1B1 | HDAC3 1878/4885HSD17B3 404/4885PARP1 4771/4885 |
| US-20030220498-A1 | Iron catalyzed cross coupling reactions of aromatic compounds | ARRB1, RBX1, CYP4X1 | HDAC3 728/4885HSD17B3 1854/4885PARP1 879/4885 |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN2, PTPN5 | HDAC3 1272/4885HSD17B3 2910/4885PARP1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.